FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2333642010> ?p ?o ?g. }

• W2333642010 endingPage "563" @default.
• W2333642010 startingPage "563.1" @default.
• W2333642010 abstract "<h3>Background</h3> It has been proved in several studies with a small number of patients that Rituximab (RTX) can prevent worsening of interstitial lung disease (ILD) and improve skin fibrosis in patients with Systemic Sclerosis (SSc). Recently, a multicentre case-control study of the EUSTAR cohort has confirmed these favorable results (Jordan S, et al. Ann Rheum Dis 2014 Jan 17[Epub ahead of print]). Moreover, RTX may be effective on calcinosis. However, little is known about its long-term effect. <h3>Objectives</h3> To assess the efficacy of RTX on skin involvement, ILD and calcinosis in patients with SSc. <h3>Methods</h3> Patients with SSc treated with RTX were recruited from 3 hospitals. At baseline, the following data were collected: gender, age, type and duration of the SSc, clinical features, modified Rodnan skin score (mRSS), HRCT, pulmonary function tests (PFTs), walking test, sPAP (measured by echo), previous and present treatments, and indication and dosage of RTX. Throughout the follow up, clinical changes, as well as changes in HRCT and PFTs, were registered. We also recorded the changes in the dosage of corticosteroids, number of RTX cycles, duration of treatment, and withdrawals. The package SPSS 17.0 was used for descriptive statistics, and quantitative variables were compared using the t-test for paired samples. <h3>Results</h3> Thirty SSc patients treated with RTX were included in the analysis. The majority were women (86.7%), with a mean age of 54 years, and a mean of 9.4 years of evolution of the disease. Subtypes: DSSc 50%, LSSc 37%, and Overlap syndromes 13.3%. The baseline mean mRSS was 15. Clinical features: ILD 80% (NSIP 67%), calcinosis 37%, pulmonary hypertension 10%, joint disease 49%. The baseline mean FVC, DLCO and TLC values were 70%, 47% and 73%, respectively. The indication for RTX was: ILD (73.4%), arthritis (36.6%), calcinosis (33.3%) and severe skin involvement (19.7%). The most used previous treatments were cyclophosphamide (50%) and mycophenolate (46.6%). RTX was always used in a RA dosage, mainly in monotherapy (46.7%), or in association with mycophenolate (40%). When data were collected, patients had received a mean of 1.7 cycles (1-5) of RTX, with a dosing interval which ranged from 6 to 15 months, and a mean of 12.8 months (1-43) of treatment. The mean mRSS was significantly reduced at follow-up (17.2±10.9 vs. 14±9.8; p=0.012), without significant changes of the HRCT (76.9%) and/or PFTs in patients with ILD. The 40% of patients with calcinosis reported improvement. There was also a good response, in terms of TJC and SJC, in patients with arthritis (p=0.024 and 0.019, respectively). The dose of corticosteroids was significantly reduced (10.1±8.8 vs. 5.3±2.9 mg, p=0.003). Two patients with severe ILD died despite RTX, and there were 3 withdrawals for various reasons. <h3>Conclusions</h3> RTX is an effective long-term therapy in SSc which can improve skin fibrosis, arthritis and calcinosis, and also prevent deterioration of ILD. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5629" @default.
• W2333642010 created "2016-06-24" @default.
• W2333642010 creator A5000726404 @default.
• W2333642010 creator A5008485597 @default.
• W2333642010 creator A5009236113 @default.
• W2333642010 creator A5020134691 @default.
• W2333642010 creator A5035309374 @default.
• W2333642010 creator A5036762020 @default.
• W2333642010 creator A5039973360 @default.
• W2333642010 creator A5042022654 @default.
• W2333642010 creator A5043000674 @default.
• W2333642010 creator A5046655135 @default.
• W2333642010 creator A5050109776 @default.
• W2333642010 creator A5055981872 @default.
• W2333642010 creator A5057349066 @default.
• W2333642010 creator A5059611543 @default.
• W2333642010 creator A5078095242 @default.
• W2333642010 creator A5078104594 @default.
• W2333642010 creator A5085847182 @default.
• W2333642010 creator A5087476255 @default.
• W2333642010 date "2014-06-01" @default.
• W2333642010 modified "2023-10-03" @default.
• W2333642010 title "FRI0485 Long-Term Efficacy of Rituximab in Systemic Sclerosis. A Spanish Multicentric Analysis" @default.
• W2333642010 doi "https://doi.org/10.1136/annrheumdis-2014-eular.5629" @default.
• W2333642010 hasPublicationYear "2014" @default.
• W2333642010 type Work @default.
• W2333642010 sameAs 2333642010 @default.
• W2333642010 citedByCount "0" @default.
• W2333642010 crossrefType "journal-article" @default.
• W2333642010 hasAuthorship W2333642010A5000726404 @default.
• W2333642010 hasAuthorship W2333642010A5008485597 @default.
• W2333642010 hasAuthorship W2333642010A5009236113 @default.
• W2333642010 hasAuthorship W2333642010A5020134691 @default.
• W2333642010 hasAuthorship W2333642010A5035309374 @default.
• W2333642010 hasAuthorship W2333642010A5036762020 @default.
• W2333642010 hasAuthorship W2333642010A5039973360 @default.
• W2333642010 hasAuthorship W2333642010A5042022654 @default.
• W2333642010 hasAuthorship W2333642010A5043000674 @default.
• W2333642010 hasAuthorship W2333642010A5046655135 @default.
• W2333642010 hasAuthorship W2333642010A5050109776 @default.
• W2333642010 hasAuthorship W2333642010A5055981872 @default.
• W2333642010 hasAuthorship W2333642010A5057349066 @default.
• W2333642010 hasAuthorship W2333642010A5059611543 @default.
• W2333642010 hasAuthorship W2333642010A5078095242 @default.
• W2333642010 hasAuthorship W2333642010A5078104594 @default.
• W2333642010 hasAuthorship W2333642010A5085847182 @default.
• W2333642010 hasAuthorship W2333642010A5087476255 @default.
• W2333642010 hasConcept C126322002 @default.
• W2333642010 hasConcept C141071460 @default.
• W2333642010 hasConcept C142724271 @default.
• W2333642010 hasConcept C180032290 @default.
• W2333642010 hasConcept C198451711 @default.
• W2333642010 hasConcept C2777543607 @default.
• W2333642010 hasConcept C2777714996 @default.
• W2333642010 hasConcept C2779338263 @default.
• W2333642010 hasConcept C2779967694 @default.
• W2333642010 hasConcept C2780653079 @default.
• W2333642010 hasConcept C71924100 @default.
• W2333642010 hasConcept C72563966 @default.
• W2333642010 hasConceptScore W2333642010C126322002 @default.
• W2333642010 hasConceptScore W2333642010C141071460 @default.
• W2333642010 hasConceptScore W2333642010C142724271 @default.
• W2333642010 hasConceptScore W2333642010C180032290 @default.
• W2333642010 hasConceptScore W2333642010C198451711 @default.
• W2333642010 hasConceptScore W2333642010C2777543607 @default.
• W2333642010 hasConceptScore W2333642010C2777714996 @default.
• W2333642010 hasConceptScore W2333642010C2779338263 @default.
• W2333642010 hasConceptScore W2333642010C2779967694 @default.
• W2333642010 hasConceptScore W2333642010C2780653079 @default.
• W2333642010 hasConceptScore W2333642010C71924100 @default.
• W2333642010 hasConceptScore W2333642010C72563966 @default.
• W2333642010 hasIssue "Suppl 2" @default.
• W2333642010 hasLocation W23336420101 @default.
• W2333642010 hasOpenAccess W2333642010 @default.
• W2333642010 hasPrimaryLocation W23336420101 @default.
• W2333642010 hasRelatedWork W1964648133 @default.
• W2333642010 hasRelatedWork W2003747311 @default.
• W2333642010 hasRelatedWork W2032136322 @default.
• W2333642010 hasRelatedWork W2038613489 @default.
• W2333642010 hasRelatedWork W2080404335 @default.
• W2333642010 hasRelatedWork W2151863779 @default.
• W2333642010 hasRelatedWork W2169903273 @default.
• W2333642010 hasRelatedWork W2206255006 @default.
• W2333642010 hasRelatedWork W4283712198 @default.
• W2333642010 hasRelatedWork W4294686196 @default.
• W2333642010 hasVolume "73" @default.
• W2333642010 isParatext "false" @default.
• W2333642010 isRetracted "false" @default.
• W2333642010 magId "2333642010" @default.
• W2333642010 workType "article" @default.